On March 1, 2023 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "the Company") reported the status of acquisition of its own shares as stated below (Press release, Astellas, MAR 1, 2023, View Source [SID1234627921]). The acquisition was implemented pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Particulars

Class of shares acquired:　　　　 　 Common stock of the Company

Total number of shares acquired:　　15,153,600 shares

Total amount of acquisition cost:　　 29,023,551,450 yen

Period of acquisition:　　　　　　　 From February 7, 2023 to February 28, 2023

Method of acquisition:　　　　　 　 Market purchase on the Tokyo Stock Exchange

(Reference)

Details of the resolution at the meeting of the Board of Directors (announced on February 6, 2023)
(1) Class of shares to be acquired:　　　　 Common stock of the Company
(2) Total number of shares to be acquired:　Up to 29 million shares
(Ratio to the total number of shares outstanding [excluding treasury stock]: 1.59%)
(3) Total amount of acquisition cost:　　　 Up to 50 billion yen
(4) Period of acquisition:　　　　　　　　 From February 7, 2023 to March 24, 2023
(5) Method of acquisition:　　　　　　　　 Market purchase on the Tokyo Stock Exchange

Accumulated Company’s own shares acquired through February 28, 2023, pursuant to the above board resolution
(1) Total number of shares acquired:　　　 15,153,600 shares
(2) Total amount of acquisition cost:　　　 29,023,551,450 yen

On March 1, 2023 2seventy bio, Inc. ("2seventy bio") (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, reported the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at a public offering price of $11.50 per share (Press release, 2seventy bio, MAR 1, 2023, View Source [SID1234627887]). All of the shares in the offering are being offered by 2seventy bio. In addition, 2seventy bio has granted the underwriters a 30-day option to purchase up to an additional 1,630,434 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about March 3, 2023, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs & Co. LLC, Cowen and Company, LLC and SVB Securites LLC are acting as joint book-running managers for the offering.

The shares of common stock are being offered by 2seventy bio pursuant to 2seventy bio’s registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2022 and became effective on November 18, 2022. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on February 28, 2023. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (866) 471-2526, facsimile: (212) 902-9316, email: [email protected]; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at [email protected] or by telephone at (833) 297-2926; or SVB Securities LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at [email protected]; or by accessing the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.